Studies have found that the CD4+ and CD8+ T cell counts are closely related to disease severity and clinical outcome, and therefore some authors proposed that CD4+ and CD8+ T cell counts in COVID-19 patients could be good biomarkers of COVID-19 activity [21,22]. This evidence concerns the gene CD8A and COVID-19.